CD248/Endosialin: A Novel Pericyte Target in Renal Fibrosis

摘要

Fibrotic diseases such as chronic kidney disease (CKD) are estimated to account for up to 45% of deaths in the industrialized world. Until recently, there have been no therapies for these diseases that include cirrhosis, idio-pathic pulmonary fibrosis, systemic sclerosis, dilated car-diomyopathy and others. In October 2014, however, the FDA approved 2 new therapies for idiopathic pulmonary fibrosis based upon convincing phase 3 trial results [1,2]. As a consequence, there is reason for optimism that new therapies for other fibrotic diseases - like CKD - may be on the horizon.